Biotech Values

[jbog]

Moreover, I don’t think the V-Pak label change will materially alter ABBV’s exclusive contract with ESRX. ABBV would have a strong legal case, IMO, if ESRX tried to change the terms of the contract other than to ensure that V-Pak isn’t given to patients where it’s now contraindicated.

You sound like this is the first contract these guys wrote and signed. Companies of this size certainly would have a remedy included for many unforeseen situations. Unfortunately, we have no clue what is in the agreement.